Volume 83, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



From April 2005 to April 2006, a phase 2 malaria vaccine trial in Kenya enrolled 400 children aged 12–47 months. Each received mixed supervised and unsupervised artemether-lumefantrine for uncomplicated malaria, using a standard six-dose regimen, by weight. Children were followed for detection of parasitemia and clinical malaria. A median of two negative malaria blood films occurred during every recurrent parasitemia (RP) episode, suggesting reinfection over late recrudescence. Median time to RP after starting artemether-lumefantrine was 37 days (36–38). Of 2,020 evaluable artemether-lumefantrine treatments, there were no RPs in 99% by day 14, 71% by day 28, and 41% by day 42. By World Health Organization standards, 71% of treatment courses had adequate responses. Although recrudescence in some cannot be ruled out, our cohort had a shorter median time to RP compared with other artemether-lumefantrine treatment studies. This underscores patient counseling on completing all treatment doses for optimal protection from RP.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. World Health Organization, 2005. World Malaria Report 2005. Available at: http://rbm.who.int/wmr2005/html/1-1.htm. Accessed April 10, 2007. [Google Scholar]
  2. Chanda P, Masiye F, Chitah BM, Sipilanyambe N, Hawela M, Banda P, Okorosobo T, , 2007. A cost-effectiveness analysis of artemether lumefantrine for the treatment of uncomplicated malaria in Zambia. Malar J 6: 21.[Crossref] [Google Scholar]
  3. Novartis, 2007. Patients benefit from artemether/lumefantrine community development. Proceedings of the American Society of Tropical Medicine and Hygiene 56th Annual Meeting, November 4–8, 2007, Philadelphia, PA. [Google Scholar]
  4. Kimani D, , 2007. New Drug Brings Down Cost of Treating Malaria. Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria. Available at: http://www.businessfightsaids.org. Accessed April 20, 2007. [Google Scholar]
  5. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, Tucker K, Waitumbi JN, Diggs C, Wittes J, Malkin E, Leach A, Soisson LA, Milman JB, Otieno L, Holland CA, Polhemus M, Remich SA, Ockenhouse CF, Cohen J, Ballou WR, Martin SK, Angov E, Stewart VA, Lyon JA, Heppner DG, Withers MR, MSP-1 Malaria Vaccine Working Group, 2009. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 4: e4708.[Crossref] [Google Scholar]
  6. Bloland PB, Boriga DA, Ruebush TK, McCormick JB, Roberts JM, Oloo AJ, Hawley W, Lal A, Nahlen B, Campbell CC, , 1999. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission II. Descriptive epidemiology of malaria infection and disease among children. Am J Trop Med Hyg 60: 641648. [Google Scholar]
  7. Ndenga B, Githeko A, Omukunda E, Munyekenye G, Atieli H, Wamai P, Mbogo C, Minakawa N, Zhou G, Yan G, , 2006. Population dynamics of malaria vectors in western Kenya highlands. J Med Entomol 43: 200206.[Crossref] [Google Scholar]
  8. Githeko AK, Ayisi JM, Odada PK, Atieli FK, Ndenga BA, Githure JI, Yan G, , 2006. Topography and malaria transmission heterogeneity in western Kenya highlands: prospects for focal vector control. Malar J 5: 107.[Crossref] [Google Scholar]
  9. Kifude CM, Polhemus ME, Heppner DG, Withers MR, Ogutu BR, Waitumbi JN, , 2007. Hb Kenya among Luo adults and young children in malaria holoendemic western Kenya: screened by high performance liquid chromatography and confirmed by polymerase chain reaction. Hemoglobin 31: 401408.[Crossref] [Google Scholar]
  10. May J, Evans JA, Timmann C, Ehmen C, Busch W, Thye T, Agbenyega T, Horstmann RD, , 2007. Hemoglobin variants and disease manifestations in severe falciparum malaria. J Am Med Assoc 297: 22202226.[Crossref] [Google Scholar]
  11. Ruwende C, Khoo SC, Snow RW, Yates SN, Kwiatkowski D, Gupta S, Warn P, Allsopp CE, Gilbert SC, Peschu N, Newbold CI, Greenwood BM, Marsh K, Hill VS, , 1995. Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature 20: 246249.[Crossref] [Google Scholar]
  12. Wambua S, Mwangi TW, Kortok M, Uyoga SM, Macharia AW, Mwacharo JK, Weatherall DJ, Snow RW, Marsh K, Williams TN, , 2006. The effect of alpha+-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya. PLoS Med 3: e158.[Crossref] [Google Scholar]
  13. Williams TN, Wambua S, Uyoga S, Macharia A, Mwacharo JK, Newton CR, Maitland K, , 2005. Both heterozygous and homozygous alpha+ thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya. Blood 106: 368371.[Crossref] [Google Scholar]
  14. Liu YT, Old JM, Miles K, Fisher CA, Weatherall DJ, Clegg JB, , 2000. Rapid detection of alpha-thalassaemia deletions and alpha-globin gene triplication by multiplex polymerase chain reactions. Br J Haematol 108: 295299.[Crossref] [Google Scholar]
  15. Waitumbi JN, Kifude CM, Polhemus ME, Heppner DG, Withers MR, Ogutu BR, , 2007. Hb G-Philadelphia or Stanleyville II? When the phenotype and genotype do not agree. Eur J Haematol 79: 177178.[Crossref] [Google Scholar]
  16. World Health Organization, 2003. Assessment and Monitoring Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. Available at: http://www.who.int/malaria/docs/ProtocolWHO.pdf. Accessed April 10, 2007. [Google Scholar]
  17. Andersen P, Borgan O, Gill RD, Keiding N, , 1993. Statistical Models Based on Counting Processes, 1st ed. New York, NY: Springer-Verlag.[Crossref] [Google Scholar]
  18. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, , 2007. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 18: e20.[Crossref] [Google Scholar]
  19. Kokwaro G, Mwai L, Nzila A, , 2007. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother 8: 7594.[Crossref] [Google Scholar]
  20. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, Rwakimari JB, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke SG, , 2006. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials 1: e7.[Crossref] [Google Scholar]
  21. van den Broek I, Kitz C, Attas SA, Libama F, Balasegaram M, Guthmann JP, , 2006. Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo. Malar J 5: 113.[Crossref] [Google Scholar]
  22. Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde RT, Rosenthal PJ, Ouedraogo JB, , 2007. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomized non-inferiority trial. Lancet 369: 491498.[Crossref] [Google Scholar]
  23. Falade CO, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI, , 2005. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 99: 459467.[Crossref] [Google Scholar]
  24. Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, Andriano K, Hunt P, de Palacios PI, , 2006. Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg 74: 991998. [Google Scholar]
  25. Bhatt KM, Samia BM, Bhatt SM, Wasunna KM, , 2006. Efficacy and safety of an artesunate/mefloquine combination, (artequin) in the treatment of uncomplicated P. falciparum malaria in Kenya. East Afr Med J 83: 236242.[Crossref] [Google Scholar]
  26. Terlouw DJ, Aidoo MA, Udhayakumar V, Kolczak MS, Oloo AJ, Kager PA, Lal A, Nahlen B, ter Kuile FO, , 2002. Increased efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria among children with sickle cell trait in western Kenya. J Infect Dis 186: 16611668.[Crossref] [Google Scholar]
  27. Nzila AM, Nduati E, Mberu EK, Hopkins SC, Monks SA, Winstanley PA, Watkins WM, , 2000. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum . J Infect Dis 181: 20232028.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 16 Jul 2009
  • Accepted : 06 Apr 2010
  • Published online : 07 Sep 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error